Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Heart failure (HF) management often involves beta-blockers to improve left ventricular (LV) function.
• Carvedilol and nebivolol are commonly prescribed beta-blockers, but their comparative short-term effects on LV systolic function in non-ischemic HF are not well-defined.
• Understanding these effects is crucial for optimizing HF treatment strategies.

Purpose of the Study:

• To compare the effects of carvedilol and nebivolol on short-term left ventricle (LV) systolic function in patients with non-ischemic heart failure (HF).
• To evaluate changes in ejection fraction (EF), ejection time (ET), isovolumic contraction time (IVCT), isovolumic relaxation time (IVRT), and myocardial performance index (MPI).

Main Methods:

• A randomized study of 61 symptomatic non-ischemic HF patients with low ejection fraction (EF ≤ 40%).
• Patients were randomized to receive either carvedilol (n=31) or nebivolol (n=30).
• Clinical and echocardiographic assessments were performed at baseline and at 3 and 6 months, evaluating LV diameters, EF, ET, IVCT, IVRT, and MPI.

Main Results:

• Both carvedilol and nebivolol significantly improved EF and MPI at 6 months, with no significant inter-group differences.
• LV diameter was reduced similarly in both groups.
• IVCT and IVRT were shortened, and ET was prolonged in both groups, without inter-group variation. Functional capacity, heart rate, blood pressure, and pro-B-type natriuretic peptide levels also showed comparable improvements.

Conclusions:

• Carvedilol and nebivolol demonstrate similar efficacy in improving short-term left ventricle systolic function in patients with non-ischemic heart failure.
• Both agents offer comparable benefits regarding echocardiographic parameters and functional capacity in this patient population.